Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDC Panel (Barely) Prefers Shingrix Shingles Vaccine Over Zostavax

Executive Summary

In 8-7 vote, Advisory Committee on Immunization Practices recommends GSK's Shingrix as preferred shingles vaccine given its higher efficacy compared to Merck's Zostavax.

You may also be interested in...



GSK’s Shingrix Vaccine Can Reach Millions More

The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.

GSK Shingrix Shingles Vaccine Could Get CDC Panel Nod For Use In Immunocompromised Adults

Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.

GSK's Big Reveal: An R&D Overhaul Poised To Yield Long-Term Cultural Change

With few near-term catalysts, GSK's R&D strategy may leave some investors underwhelmed, but President-R&D Hal Barron is focused on making deep cultural and scientific changes at the big pharma. He laid out his initial turnaround plan July 25. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel